SCHEMBL3974635

SCHEMBL3974635

CCCCNc1nc(-c2ccc(Br)cc2)nc2ccc(Cl)cc12

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ACP1 P24666 1/20 0.58
SLC2A1 P11166 1/20 0.54
ADORA3 P0DMS8 2/20 0.53
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
POLB P06746 2/20 0.53
LATS1 O95835 2/20 0.51
LATS2 Q9NRM7 2/20 0.51
MAPT P10636 3/20 0.49
TP53 P04637 1/20 0.49
LMNA P02545 2/20 0.48
NPSR1 Q6W5P4 2/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
PDE5A O76074 3/20 0.48
FLT3 P36888 2/20 0.45
MAPK1 P28482 1/20 0.45
GBA1 P04062 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3974901 0.88 SLC2A1 (0.72) SLC2A1MEN1KMT2APOLBFLT3
SCHEMBL3975234 0.87 ACP1 (0.60) ACP1SLC2A1MEN1KMT2APOLB
SCHEMBL3980413 0.85 SLC2A1 (0.62) SLC2A1MEN1KMT2APOLBLMNA
SCHEMBL3971156 0.85 POLB (0.60) ACP1SLC2A1POLBFLT3MAPK1
SCHEMBL3980578 0.83 MAPK1 (0.58) ACP1MEN1KMT2AMAPTTP53
SCHEMBL27599077 0.81 MEN1 (0.43) ACP1SLC2A1ADORA3MEN1KMT2A
SCHEMBL3972870 0.80 SLC2A1 (0.70) SLC2A1MEN1KMT2APOLBMAPT
SCHEMBL3974654 0.80 ACP1 (0.54) ACP1SLC2A1MEN1KMT2APOLB
SCHEMBL3974486 0.80 MAPT (0.74) ACP1MEN1KMT2APOLBMAPT
SCHEMBL3977603 0.80 PDE5A (0.70) MEN1KMT2AMAPTTP53LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7547702-B2 4-amino-quinazolines ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2009-06-16 US disclosed
US-20060019974-A1 Glycoprotein antagonist; anticholesterol agents; cardiovascular disorders; strokes; antiischemic agents ORTHO-MCNEIL PHARMACEUTICALS, INC. 2006-01-26 US disclosed
WO-2004030672-A1 USE OF 4 AMINO-QUINAZOLINES AS ANTI CANCER AGENTS MERCK PATENT GMBH (DE) 2004-04-15 WO disclosed
CN-1474815-A 4-amino-quinazolines Ĭ��ר���ɷ����޹�˾ 2004-02-11 CN disclosed
EP-1318984-A1 4-AMINO-QUINAZOLINES MERCK PATENT GmbH (DE) 2003-06-18 EP disclosed
WO-2002024667-A1 4-AMINO-QUINAZOLINES MERCK PATENT GMBH (DE) 2002-03-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060019974-A1 Glycoprotein antagonist; anticholesterol agents; cardiovascular disorders; strokes; antiischemic agents SERPINA3, APOL1, MGAT3 ACP1 4097/4885SLC2A1 1107/4885ADORA3 448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.